ArticlePloS one2025
Validation in diabetic rats of a fully automated insulin delivery system based on impulsive offset-free MPC control.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of an impulsive automated insulin delivery system (i-AiDS) for type 1 diabetes mellitus aims to provide real-time blood glucose regulation with minimal human intervention. This study presents the validation of an offset-free impulsive zone model predictive control strategy designed to cope with external disturbances such as meal intake and plant-model mismatch in a diabetic rat model. Fourteen male Wistar rats induced diabetes with streptozotocin were monitored using an continuous glucose monitoring and regulated by delivering insulin with a customized low-cost pump. After acquiring diabetes condition, the procedure for installing the devices in the rat is carried out. During the first day, manual insulin injections are made by the pump, the glucose response is recorded by the interface and an off-line parametric estimation is executed. Based on the parameters found, simulations are used for the first tuning of the controller and the estimator. During the second day, the parameters of the model and the control are tested and adjusted. Finally, on the third day, a 72-hour test of the impulsive begins in full autonomous mode. Results showed that the controller achieved an average of 83.4% of the time within the target range of 80-180 mg/dL, with no severe hypoglycemic or hyperglycemic events. The median absolute relative difference between model predictions and actual sensor data was 24.66%, indicating the presence of plant-model mismatch that was effectively handled by the controller. Peak hyperglycemic events reached 320 mg/dL, but were regulated within 50 minutes, while mild hypoglycemic events occurred in 3.62 ± 1.8 cases per subject. The study demonstrates the efficacy of the controller in managing unannounced carbohydrate intake and physiological disturbances in a real-world preclinical environment. These findings provide a foundation for future clinical trials, emphasizing the importance of in vivo validation of control strategies to refine the i-AiDS for human use. Improvements in model accuracy and dynamic parameter tuning could further enhance performance, particularly in longer experimental periods.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.